NEW YORK, Dec. 13 – Biosimulation company Entelos has agreed to prioritize asthma drug candidates for Pfizer.
Entelos of Menlo Park, Calif., said Wednesday it would use its Asthma PhysioLab technology to analyze how people with and without asthma react to the treatments and to determine the appropriate treatment dosages.
Entelos will receive research funding and license fees from Pfizer as well as milestone payments for reaching particular objectives and novel findings and biomarkers.
"Over the last year, our capability and experience in applying in silico science and PhysioLab technology throughout the entire spectrum of drug discovery and development has increased tremendously,” James Karis, CEO of Entelos, said in a statement.
Entelos has developed a mathematical model of asthma in humans, which the company said it can use to simulate the disease as well as a patient’s responsiveness to drugs. Entelos said it can use its technology to identify novel pathways, speed up the drug development process, and better understand varying patient responsiveness to the treatments.
Entelos has PhysioLab systems for other diseases, including obesity, diabetes, and adipocytes.